Our Pipeline

We are passionately advancing a pipeline of multiple essential biosimilars (insulin and insulin analogues) in diabetes therapeutic area with a laser focus on efficient and fast track development within the framework of rigorous scientific/technical principles and global regulatory expectations.

GeneSys Biosimilar pipeline is highly attractive and consists of 6 insulin/insulin analogues biosimilars covering, long-acting, rapid acting and intermediate acting products for global patients. GeneSys biosimilar portfolio targets > US$30 billion market opportunity of reference products (Ref: IMS 2016). Four biosimilar candidates are completed upto toxicology studies and shortly progressing to clinical trials.